Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 23, Issue 5, 1996, Pages 983-989

  Griffith, David E ^a   Brown, Barbara A ^a   Girard, William M ^a   Murphy, David T ^a   Wallace Jr , Richard J ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG INFECTION; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; SPUTUM CULTURE;

EID: 0029965596     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.5.983     Document Type: Article

References (19)

1. Dutt AK, Stead WW. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med 1979;67:449-53.
2. Davidson PT, Khanijo V, Goble M, Moulding TS. Treatment of disease due to Mycobacterium intracellulare. Rev Infect Dis 1981;3:1052-9.
3. Etzkorn ET, Aldarondo S, McAllister CK, Matthews J, Ognibene AJ. Medical therapy of Mycobacterium avium-intracellulare pulmonary disease. Am Rev Respir Dis 1986;134:442-5.
4. Ahn CH, Ahn SS, Anderson RA, Murphy DT, Mammo A. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1986;134:438-41.
5. Hornick DB, Dayton CS, Bedell GN, Fick RB Jr. Nontuberculous mycobacterial lung disease: substantiation of a less aggressive approach. Chest 1988;93:550-5.
6. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease: incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis 1991;143:1381-5.
7. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
8. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994;121:905-11.
9. Dautzenberg B, Saint Marc T, Meyohas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993;153:368-72.
10. 9a.Shafron SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83.
11. Wallace RJ Jr, Brown B A, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. American Journal of Respiratory and Critical Care Medicine 1994;149:1335-41.
12. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin J-P, the Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995;107:1035-40.
13. Wallace RJ Jr, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. American Journal of Respiratory and Critical Care Medicine 1996;153:1766-72.
14. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993;16:215-21.
15. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
16. The DATRI Study Group. Coadministration of clarithromycin alters the concentration-time profile of rifabutin [abstract no. A2]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology, 1994.
17. Griffith DE, Brown B A, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-8.
18. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747-50.
19. Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 1991;338:1107-9.